HLA-A and neoplasm: In order to fully exploit the tumor patients’ T cell repertoire directed against all six HLA-A,B,C allotypes, we developed a new platform termed MediMer (MHC-I, empty, single-chain dimer) based on disulfide-stabilized peptide-free β2m–MHC-I heavy chain single-chain dimers (dsSCD) that are produced in metabolically biotinylated form by CHO-S producer cells without the need of additional steps such as in vitro refolding.